Use of &agr;-linolenic acid metabolites for treatment or prevention of cancer
US6340705B1 · kind B1 · utility
13Cited by
12References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 1999 |
| Grant date | Jan 22, 2002 |
| Priority date | — |
| Expiry date | Nov 26, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cancer in a mammal can be treated or prevented by administering to a mammal in need thereof a cancer inhibiting amount of metabolite(s) of &agr;-linolenic acid, such as stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosaptentaenic acid (22:5 n-3) and mixtures thereof, especially metabolites including stearidonic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.